Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIL-214 Norovirus Vaccine in Infants (NEST-IN1)
NCT05281094Phase 3Terminated
- Sponsor
- HilleVax
- Start
- Apr 2022
- Primary completion
- Dec 2023
- Modality
- Recombinant Protein Vaccines
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of NoV GI.1/GII.4 bivalent VLP vaccine in norovirus infection and gastroenteritis, sponsored by HilleVax. Primary endpoint: Efficacy of HIL-214 Against Moderate/Severe Acute Gastroenteritis Associated Only With GI.1 or GII.4 Norovirus Genotypes. Started Apr 2022; status: terminated.
02
Drugs
NoV GI.1/GII.4 bivalent VLP vaccine
03
Conditions
norovirus infectiongastroenteritis
Beyond the preview
Go deeper on NCT05281094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05281094.